Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)

Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT) is a phase 2, interventional study registered as NCT06770270 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 68 participants, started 2024-08-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: Pucotenlimab. Conditions listed: Rectal Cancer. Primary outcome: The rate of cCR; The rate of pCR. Colorectal eligibility wording from the registry: "Histologically confirmed and evaluated as locally advanced rectal adenocarcinoma (confirmed by MRI): cT3 or higher; or cN+;". Sites: China. No results are recorded here; the registry entry is the source.